Liquidia Corporation Common Stock vs Vanguard Ultra Short Bond ETF — how do they compare? Liquidia Corporation Common Stock trades at $33.69 (market cap $2.40B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is far larger — about 4.3× Liquidia Corporation Common Stock's market cap, and Liquidia Corporation Common Stock is more actively traded (2,857,547 versus 1,227,697). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Vanguard Ultra Short Bond ETF for 64 Days on average.
| LQDA | VUSB | |
|---|---|---|
Market Cap | $2.40B | $10.20B |
Volume | 2,857,547 | 1,227,697 |
Sector | Health | Leveraged / Inverse |
52-Week High | $91.03 | $50.03 |
52-Week Low | $22.02 | $49.41 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VUSB is trading at $49.475, showing minimal daily movement with a slight decline of 0.01%. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF maintains consistent dividend distributions, with recent payments of $0.17-0.18 per share. Market sentiment is influenced by Federal Reserve interest rate expectations, positioning short-term bond ETFs favorably amid potential rate increases.
The outlook for VUSB remains cautious due to bearish technical signals and interest rate sensitivity. Investment opportunity exists for investors seeking short-term bond exposure with regular income, though risks include Fed policy shifts and market volatility. The ETF's stability and dividend consistency provide defensive characteristics in uncertain rate environments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →